The agreement grants Caribou the right to its fully human anti-CD371 single-chain variable fragment (scFv) product. It also grants the company the right to intellectual property related to the field of allogeneic CD371-targeted cell therapies including chimeric antigen receptor (CAR)-T, CAR-natural killer (NK), or induced pluripotent stem cell (iPSC)-derived cell products. The antibody fragments will be used to create therapies for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS).

The anti-CD371 scFvs were developed in a lab at MSK in collaboration with the Tri-Institutional Therapeutic Discovery Institute, a nonprofit drug discovery company wholly owned by MSK, Weill Cornell Medicine, and the Rockefeller University.

The financial terms of the agreement were not disclosed.

Precigen doses first patients with UltraCAR-T cells
Precigen said that the first patients in two phase I clinical trials have been treated with UltraCAR-T cells manufactured by its UltraPorator system.

Improving the safety of gene therapies 2 different ways
Two groups of researchers have developed unique approaches to overcome the limitations of delivery of gene editing therapeutics. In a pair of new papers,...

Intellia to advance CRISPR treatment for sickle cell
Intellia Therapeutics has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease treatments using its CRISPR/Cas9...

Caribou, MaxCyte enter CRISPR license agreement
Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program.